Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Protocol: Neoadj Pembrolizumab + TP for her2+ Breast Cancer
Single-arm, phase 2 trial (WSG-KEYRICHED-1, NCT03988036) Patients with HER2-positive early-stage (cT1c-T3/N0-1/M0) breast cancer Pembrolizumab + trastuzumab + pertuzumab for 12 wks
New Indication: Neoadjuvant Durvalumab with CISplatin/Gemcitabine for Upper GU Tract Cancer
Phase 2, multicenter, open-label, nonrandomized trial (iNDUCT-GETUG V08) High-risk, operable upper tract urothelial carcinoma (UTUC), M0, eligible for radical nephroureterectomy Du
New Reference: Neoadjuvant Dostarlimab for dMMR Tumors
Phase 2, single-arm, multicenter study (NCT04165772) Patients with stage I-III dMMR solid tumors amenable to curative surgery, including rectal and nonrectal sites Neoadjuvant dost
New Reference: Belzutifan for vHL Associated Tumors
Single-arm, phase 2 trial (LITESPARK-004) VHL disease patients with RCC, CNS hemangioblastomas, or pancreatic NETs Belzutifan 120 mg orally once daily
New Protocol: Atezolizumab with Carbo-Pem-Bev for Pleural Mesothelioma
Randomized, open-label, phase 3 trial (BEAT-meso) Unresectable, untreated pleural mesothelioma patients Atezolizumab + cisplatin + pemetrexed + bevacizumab (Atezo-CPB) vs. cisplati
New Protocol: Atezolizumab and Trastuzumab with CapeOx for Periop Her2+ Gastric Cancer
Open-label, randomized, phase 2 trial (NCT04661150) Resectable, HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma Atezolizumab + trastuzumab + XELOX (arm A)
New Reference: Acalabrutinib with R-Bendamustine in Untreated Mantle Cell Lymphoma
Randomized, double-blind, phase 3 trial (ECHO, NCT02972840) Previously untreated mantle cell lymphoma patients ≥65 years Acalabrutinib + bendamustine + rituximab (ABR) vs. placeb
New Reference: Taletrectinib for ROS1-Positive NSCLC
Phase 2, open-label, single-arm, multicenter trials (TRUST-I and TRUST-II) ROS1-positive advanced or metastatic NSCLC Taletrectinib 600 mg once daily
